Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.
Read the paper here
Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
